Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genetic Testing Could Identify HIV Patients At Risk Of Hypersensitivty To HIV Drug

01.03.2002


HIV patients at risk of a potentially fatal hypersensitive reaction to the antiretroviral drug abacavir could be identified by genetic testing before drug therapy has started, suggest authors of a fast-track study in this week’s issue of THE LANCET.



The use of the HIV antiretroviral drug abacavir, a potent HIV-1 nucleoside-analogue reverse-transcriptase inhibitor, is complicated by a potentially life-threatening hypersensitivity syndrome in about 5% of cases. Genetic factors influencing the immune response to abacavir might result in some individuals being more susceptible to a hypersensitive reaction than other patients.

Simon Mallal and colleagues from the Royal Perth Hospital, Australia, studied 200 HIV patients treated with abacavir. They focused on analysis of the MHC genes that are known to be associated with the immune response.


Abacavir hypersensitivity was identified in 18 patients, and drug tolerance was confirmed in 167 patients after 6 weeks of therapy. Patients with the allele (gene component) HLA-B*5701 were over 100 times more likely to be hypersensitive to abacavir; this allele was present in 14 (78%) of the 18 patients with abacavir hypersensitivity, and in four (2%) of the 167 abacavir-tolerant patients. The genetic region marked by the combination HLA-B*5701, HLA-DR7, and HLA-DQ3 (the 57.1 ancestral haplotype) was present in 13 (72%) hypersensitive patients and none of the tolerant patients. All patients with the full 57.1 ancestral haplotype experienced abacavir hypersensitivity.

Simon Mallal comments: “The findings have important clinical implications. In our population, withholding abacavir in patients with this haplotype would be expected to reduce the prevalence of this potentially life-threatening event from 9% to 2.5 % without inappropriately denying the drug to any patients. Based on these data it is our current practice to withhold abacavir in patients who have the HLA-B*5701,-DR7,-DQ3 haplotype. However, before such practice can be taken up by others it is essential that the association between HLA type and abacavir hypersensitivity in their own populations is assessed.”

He adds: “However, there were four patients in the study who developed abacavir hypersensitivity in whom no part of the susceptibility haplotype could be identified. Therefore, HLA typing at these alleles could not be used to completely exclude the risk of a future reaction, and the current clinical approach of high vigilance for these reactions must continue.”

In an accompanying Commentary (p 722), Amalio Telenti from University Hospital, Lausanne, Switzerland,concludes: “From recent developments in human genetics, a need for a more comprehensive analysis, including dozens or hundreds of genes, can be predicted. This analysis may become feasible by use of microarrays that allow interrogation of multiple genes simultaneously. Decisions about the best time to start therapy, and the most effective and least toxic drug combinations, may be based on particular genotype profiles. This projection may look far-fetched, with just a few relevant genes identified, but these are the first drops before a downpour.”

Richard Lane | alphagalileo

More articles from Health and Medicine:

nachricht Antibiotic effective against drug-resistant bacteria in pediatric skin infections
17.02.2017 | University of California - San Diego

nachricht Tiny magnetic implant offers new drug delivery method
14.02.2017 | University of British Columbia

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Biocompatible 3-D tracking system has potential to improve robot-assisted surgery

17.02.2017 | Medical Engineering

Real-time MRI analysis powered by supercomputers

17.02.2017 | Medical Engineering

Antibiotic effective against drug-resistant bacteria in pediatric skin infections

17.02.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>